Skip to main content
CHUGAI PHARMACEUTICAL CO., LTD. logo

CHUGAI PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 4519 ISIN · JP3519400000 LEI · 529900T9LAII161DCN95 T Manufacturing
Open in API
Filings indexed 77 across all filing types
Latest filing 2026-03-25 Regulatory Filings
Country JP Japan
Listing T 4519

About CHUGAI PHARMACEUTICAL CO., LTD.

https://www.chugai-pharm.co.jp/english/

Chugai Pharmaceutical Co., Ltd. is a research and development-driven pharmaceutical company dedicated to creating innovative medical products to address unmet medical needs. As a member of the Roche Group, Chugai leverages its advanced expertise in biotechnology and science to develop novel treatments, establishing a leading position in therapeutic antibodies. The company's strategy emphasizes a shift towards discovery research and early clinical development, the integration of digital technologies, and open innovation through external partnerships. Its core therapeutic areas include oncology, rheumatology, and haemophilia, where it provides biopharmaceuticals and molecular targeted therapies to patients.

Recent filings

Filing Released Lang Actions
確認書
Regulatory Filings Classification · 1% confidence The document is a Japanese confirmation letter (確認書) filed under the Financial Instruments and Exchange Act (金融商品取引法第24条の４の２第１項) certifying the accuracy of the 2025 annual securities report (有価証券報告書). It is not the full annual report itself, nor an investor presentation, earnings release, or other defined category. It is a statutory regulatory submission which does not fit more specific categories, so it falls into the general Regulatory Filings category (RNS).
2026-03-25 Japanese
有価証券報告書－第115期(2025/01/01－2025/12/31)
Annual Report Classification · 1% confidence The document is a Japanese 'Yuka Shoken Hokokusho' (Securities Report), which is the Japanese equivalent of an Annual Report (10-K). It contains the official header, fiscal year information (2025-01-01 to 2025-12-31), and detailed financial data, confirming it is the comprehensive annual financial filing rather than an announcement or summary. FY 2025
2026-03-25 Japanese
確認書
Regulatory Filings Classification · 1% confidence The document is a 'Confirmation Letter' (確認書) filed under the Financial Instruments and Exchange Act. It serves as an officer certification by the CEO and CFO regarding the accuracy of the company's interim report. Per the 'Certification Rule', documents that are primarily officer certifications or attestations should be classified as Regulatory Filings (RNS), even if they reference a specific report type. H1 2025
2025-07-25 Japanese
半期報告書－第115期(2025/01/01－2025/12/31)
Interim / Quarterly Report Classification · 1% confidence The document is a '半期報告書' (Semi-Annual Report) for Chugai Pharmaceutical Co., Ltd., covering the period from January 1, 2025, to June 30, 2025. It contains detailed financial statements, management analysis (MDA), and operational updates, which are characteristic of an interim financial report. According to the filing definitions, a comprehensive financial report for a period shorter than a full fiscal year is classified as an Interim / Quarterly Report (IR). H1 2025
2025-07-25 Japanese
訂正臨時報告書
Share Issue/Capital Change Classification · 1% confidence The document is titled '臨時報告書' (Extraordinary Report) and is filed with the Kanto Local Finance Bureau ('関東財務局長'). The filing date is March 27, 2025. The content explicitly states the reason for filing under Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act and Article 19, Paragraph 2, Item 2-2 of the Cabinet Office Ordinance on Disclosure of Corporate Information. The subject matter is the resolution by the Board of Directors to allot treasury shares ('自己株式の処分') to directors, executive officers, and employees under a restricted stock compensation plan ('譲渡制限付株式報酬制度'). This structure—a formal report detailing a specific corporate action (share allotment/compensation) filed outside of the regular annual (10-K) or quarterly (IR) cycle—is characteristic of a Japanese Extraordinary Report (or Tender Offer Report, etc., depending on the specific content). Given the options, this document details a specific corporate action (share compensation/allotment) that is not a standard annual report, earnings release, or dividend notice. In the context of the provided codes, this type of specific, non-periodic corporate action filing, especially one related to compensation and capital structure changes, often falls under a general regulatory filing category if a more specific one isn't available. However, the core action is the issuance of shares as compensation, which relates to capital structure. Since it is a formal, detailed report on a specific transaction (share allotment to management/employees), it is best classified as a general Regulatory Filing (RNS) or potentially related to Capital/Financing (CAP) or Remuneration (DEF 14A). Since the document is a full, detailed report (not just an announcement of a report) and concerns compensation/share issuance, and given the Japanese context where '臨時報告書' is a broad category, RNS (Regulatory Filings) is the most appropriate fallback for specific, non-standard disclosures. If we strictly map the content to the definitions: it details compensation ('DEF 14A' covers remuneration, but this is a detailed share issuance report, not just a proxy statement) and capital change ('CAP' or 'SHA'). Since it is a formal filing ('臨時報告書') detailing a specific corporate event, RNS is the safest general classification for non-standard disclosures not covered by the primary codes like 10-K or IR. Given the detailed nature and the fact it's a formal filing, RNS is appropriate as a catch-all for specific regulatory disclosures not matching the other categories perfectly.
2025-04-22 Japanese
臨時報告書
AGM Information Classification · 1% confidence The document is titled '臨時報告書' (Extraordinary Report) and explicitly states in Section 1 ('提出理由') that it is being submitted based on Article 24-5, Paragraph 4 of the Financial Instruments and Exchange Act because resolutions were made at the company's 114th Annual General Meeting (AGM) held on March 27, 2025. Section 2 details the resolutions, including dividend approval and the election/re-election of directors and auditors, along with the voting results (votes for, against, abstentions, and approval rates). This content perfectly matches the definition of reporting the results of a shareholder vote following a general meeting. The most specific code for this is 'DVA' (Declaration of Voting Results & Voting Rights Announcements). Although it relates to an AGM, the core purpose is reporting the *results* of the vote, not general AGM materials (AGM-R) or proxy solicitation (PSI).
2025-03-28 Japanese

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.